| Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 170 (6), 1109-1119. e10, 2017 | 1251 | 2017 |
| Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double … GV Long, R Dummer, O Hamid, TF Gajewski, C Caglevic, S Dalle, ... The Lancet Oncology 20 (8), 1083-1097, 2019 | 677 | 2019 |
| Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases α and δ SJ Diede, DE Gottschling Cell 99 (7), 723-733, 1999 | 491 | 1999 |
| Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma C Robert, A Ribas, O Hamid, A Daud, JD Wolchok, AM Joshua, WJ Hwu, ... Journal of clinical oncology 36 (17), 1668-1674, 2018 | 442 | 2018 |
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ... The Lancet 399 (10336), 1718-1729, 2022 | 305 | 2022 |
| The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku SE Peterson, AE Stellwagen, SJ Diede, MS Singer, ZW Haimberger, ... Nature genetics 27 (1), 64-67, 2001 | 303 | 2001 |
| Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of … B Geoerger, HJ Kang, M Yalon-Oren, LV Marshall, C Vezina, A Pappo, ... The Lancet Oncology 21 (1), 121-133, 2020 | 243 | 2020 |
| Exonuclease activity is required for sequence addition and Cdc13p loading at a de novo telomere SJ Diede, DE Gottschling Current Biology 11 (17), 1336-1340, 2001 | 174 | 2001 |
| DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences SJ Diede, J Guenthoer, LN Geng, SE Mahoney, M Marotta, JM Olson, ... Proceedings of the National Academy of Sciences 107 (1), 234-239, 2010 | 159* | 2010 |
| Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. C Robert, A Ribas, O Hamid, A Daud, JD Wolchok, AM Joshua, WJ Hwu, ... Journal of Clinical Oncology 34 (15_suppl), 9503-9503, 2016 | 148 | 2016 |
| Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 174 (4), 1031-1032, 2018 | 142 | 2018 |
| Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. GV Long, R Dummer, O Hamid, T Gajewski, C Caglevic, S Dalle, ... Journal of Clinical Oncology 36 (15_suppl), 108-108, 2018 | 142 | 2018 |
| KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma PF Ferrucci, AM Di Giacomo, M Del Vecchio, V Atkinson, H Schmidt, ... Journal for immunotherapy of cancer 8 (2), 2020 | 141 | 2020 |
| A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151) L Si, X Zhang, Y Shu, H Pan, D Wu, J Liu, F Lou, L Mao, X Wang, X Wen, ... Translational oncology 12 (6), 828-835, 2019 | 108 | 2019 |
| MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state Z Yang, KL MacQuarrie, E Analau, AE Tyler, FJ Dilworth, Y Cao, SJ Diede, ... Genes & development 23 (6), 694-707, 2009 | 108 | 2009 |
| Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma JA Chesney, A Ribas, GV Long, JM Kirkwood, R Dummer, I Puzanov, ... Journal of Clinical Oncology 41 (3), 528, 2023 | 82 | 2023 |
| Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors KL MacQuarrie, Z Yao, AP Fong, SJ Diede, ER Rudzinski, DS Hawkins, ... Molecular and cellular biology, 2013 | 79 | 2013 |
| Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas SE Mahoney, Z Yao, CC Keyes, SJ Tapscott, SJ Diede Epigenetics 7 (4), 400-408, 2012 | 77 | 2012 |
| A duplication at chromosome 11q12. 2–11q12. 3 is associated with spinocerebellar ataxia type 20 MA Knight, D Hernandez, SJ Diede, HG Dauwerse, I Rafferty, ... Human molecular genetics 17 (24), 3847-3853, 2008 | 77 | 2008 |
| Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma C Robert, WJ Hwu, O Hamid, A Ribas, JS Weber, AI Daud, FS Hodi, ... European Journal of Cancer 144, 182-191, 2021 | 68 | 2021 |
